Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001181431-14-031922
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-09-15 14:41:46
Reporting Period:
2014-09-15
Filing Date:
2014-09-15
Accepted Time:
2014-09-15 14:41:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1382911 Orexigen Therapeutics Inc. OREX Pharmaceutical Preparations (2834) 651178822
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380022 Michael Narachi C/o Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla CA 92037
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-15 50,000 $4.78 58,026 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. Weighted average from 9 transactions with prices ranging from $4.685 to $4.870. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will undertake to provide full information regarding the number of shares purchased at each separate price.
  2. Includes 4,046 shares acquired under the Issuer's Employee Stock Purchase Plan on May 30, 2014.